The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients
暂无分享,去创建一个
S. Parajuli | Neetika Garg | D. Mandelbrot | Jeannina A Smith | J. Odorico | M. Jorgenson | J. Descourouez | Christopher M Saddler
[1] N. Khardori,et al. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report. , 2021, Transplantation proceedings.
[2] G. Gupta,et al. Letermovir prophylaxis in solid organ transplant—Assessing CMV breakthrough and tacrolimus drug interaction , 2021, Transplant infectious disease : an official journal of the Transplantation Society.
[3] F. Thalhammer,et al. Letermovir for the compassionate therapeutic use of cytomegalovirus infection , 2020, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
[4] T. Berney,et al. Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient. , 2020, Transplantation.
[5] C. Strassburg,et al. Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient , 2020, European journal of case reports in internal medicine.
[6] Deepali Kumar,et al. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients. , 2020 .
[7] N. Kneidinger,et al. Letermovir for difficult to treat cytomegalovirus infection in lung transplant recipients , 2020, Pneumologie.
[8] S. Nathan,et al. Single‐center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients , 2019, Transplant infectious disease : an official journal of the Transplantation Society.
[9] W. Kraft,et al. Pharmacokinetic Drug‐Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil , 2019, Journal of clinical pharmacology.
[10] A. Humar,et al. Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice , 2019, Clinical transplantation.
[11] D. Grewal,et al. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis , 2019, Antimicrobial Agents and Chemotherapy.
[12] S. Chou,et al. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir‐resistant cytomegalovirus infection , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] S. Chou,et al. Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing , 2014, Antimicrobial Agents and Chemotherapy.
[14] Klemens Budde,et al. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study , 2014, Transplant international : official journal of the European Society for Organ Transplantation.
[15] E. Cordero,et al. Use of High-Dose Ganciclovir for the Treatment of Cytomegalovirus Replication in Solid Organ Transplant Patients With Ganciclovir Resistance-Inducing Mutations , 2013, Transplantation.
[16] H. Zimmermann,et al. The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase , 2011, Journal of Virology.
[17] H. Zimmermann,et al. First Report of Successful Treatment of Multidrug‐Resistant Cytomegalovirus Disease with the Novel Anti‐CMV Compound AIC246 , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[18] A. Caliendo,et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation , 2010, Transplantation.
[19] J. L. Stern,et al. Immunomodulatory Properties of a Viral Homolog of Human Interleukin-10 Expressed by Human Cytomegalovirus during the Latent Phase of Infection , 2008, Journal of Virology.